H.R. 6832 · 117th Congress
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
- Stage
- In committee
- Sponsor
- Michael Cloud
- Introduced
- 2022-02-25
- Latest action
- 2022-02-28 · Referred to the Subcommittee on Health.
Subjects
Health care coverage and access
Public contracts and procurement
Presidents and presidential powers, Vice Presidents
Military procurement, research, weapons development
Health
State and local government operations
Infectious and parasitic diseases
Health programs administration and funding
Drug therapy
Health technology, devices, supplies
Emergency medical services and trauma care
Cardiovascular and respiratory health
Intergovernmental relations
Drug safety, medical device, and laboratory regulation